Capital Group Private Client Services Inc. Sells 9,489 Shares of Astrazeneca Plc $AZN

Capital Group Private Client Services Inc. reduced its stake in Astrazeneca Plc (NYSE:AZN) by 10.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 84,027 shares of the company’s stock after selling 9,489 shares during the quarter. Capital Group Private Client Services Inc.’s holdings in Astrazeneca were worth $14,747,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Kestra Investment Management LLC raised its holdings in Astrazeneca by 1.9% in the 4th quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock valued at $595,000 after acquiring an additional 63 shares during the period. Luken Investment Analytics LLC raised its holdings in Astrazeneca by 4.3% in the 4th quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock valued at $274,000 after acquiring an additional 64 shares during the period. Addison Advisors LLC raised its holdings in Astrazeneca by 3.9% in the 4th quarter. Addison Advisors LLC now owns 1,736 shares of the company’s stock valued at $305,000 after acquiring an additional 65 shares during the period. Western Wealth Management LLC raised its holdings in Astrazeneca by 2.5% in the 4th quarter. Western Wealth Management LLC now owns 2,887 shares of the company’s stock valued at $507,000 after acquiring an additional 71 shares during the period. Finally, Soltis Investment Advisors LLC raised its holdings in Astrazeneca by 2.2% in the 4th quarter. Soltis Investment Advisors LLC now owns 3,470 shares of the company’s stock valued at $609,000 after acquiring an additional 76 shares during the period. 20.35% of the stock is owned by institutional investors.

Astrazeneca Stock Performance

Shares of NYSE:AZN opened at $186.06 on Friday. Astrazeneca Plc has a 1 year low of $137.23 and a 1 year high of $212.71. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The stock has a market capitalization of $288.57 billion, a price-to-earnings ratio of 27.94, a price-to-earnings-growth ratio of 1.59 and a beta of 0.25. The company’s 50 day simple moving average is $190.84 and its 200 day simple moving average is $185.12.

Astrazeneca (NYSE:AZN) last issued its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The firm had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. As a group, research analysts predict that Astrazeneca Plc will post 9.52 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

AZN has been the subject of a number of analyst reports. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Weiss Ratings initiated coverage on shares of Astrazeneca in a research report on Wednesday, March 11th. They issued a “buy (b)” rating for the company. DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a research report on Thursday, May 21st. Finally, Barclays reiterated a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. Twelve investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.